DE3769221D1 - Traegermassen fuer die kontrollierte freisetzung pharmazeutischer wirkstoffe. - Google Patents

Traegermassen fuer die kontrollierte freisetzung pharmazeutischer wirkstoffe.

Info

Publication number
DE3769221D1
DE3769221D1 DE8787107438T DE3769221T DE3769221D1 DE 3769221 D1 DE3769221 D1 DE 3769221D1 DE 8787107438 T DE8787107438 T DE 8787107438T DE 3769221 T DE3769221 T DE 3769221T DE 3769221 D1 DE3769221 D1 DE 3769221D1
Authority
DE
Germany
Prior art keywords
controlled release
active substances
pharmaceutical active
supporting measures
measures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787107438T
Other languages
English (en)
Inventor
Benjamin Oshlack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mundipharma GmbH
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25390936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3769221(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of DE3769221D1 publication Critical patent/DE3769221D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
DE8787107438T 1986-07-18 1987-05-22 Traegermassen fuer die kontrollierte freisetzung pharmazeutischer wirkstoffe. Expired - Lifetime DE3769221D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/887,340 US4861598A (en) 1986-07-18 1986-07-18 Controlled release bases for pharmaceuticals

Publications (1)

Publication Number Publication Date
DE3769221D1 true DE3769221D1 (de) 1991-05-16

Family

ID=25390936

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787107438T Expired - Lifetime DE3769221D1 (de) 1986-07-18 1987-05-22 Traegermassen fuer die kontrollierte freisetzung pharmazeutischer wirkstoffe.

Country Status (22)

Country Link
US (1) US4861598A (de)
EP (1) EP0253104B1 (de)
JP (2) JP2511054B2 (de)
KR (1) KR930008954B1 (de)
CN (1) CN1029770C (de)
AT (1) ATE62404T1 (de)
AU (1) AU596183B2 (de)
CA (1) CA1296633C (de)
DE (1) DE3769221D1 (de)
DK (1) DK175627B1 (de)
DZ (1) DZ1112A1 (de)
EG (1) EG18574A (de)
ES (1) ES2033259T3 (de)
FI (1) FI87045C (de)
GR (1) GR3001788T3 (de)
IL (1) IL82604A (de)
IN (1) IN166546B (de)
MX (1) MX163284A (de)
NO (1) NO169998C (de)
NZ (1) NZ220406A (de)
PT (1) PT85353B (de)
ZA (1) ZA874038B (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IL109944A (en) * 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
EP0647448A1 (de) * 1993-10-07 1995-04-12 Euroceltique S.A. Oral verabreichbare, Opioid-Analgetika enthaltende Arzneimittel mit verlängerter Wirkung
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
ES2097087B1 (es) * 1994-08-01 1997-12-16 Univ Sevilla Sistema de liberacion controlada de morfina y otros farmacos solubles en agua por complejacion con sustancias polimericas.
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
JPH1050306A (ja) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd 水素吸蔵合金電極の製造方法
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
KR100417489B1 (ko) 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 효능제／길항제 혼합물
WO2000016776A1 (fr) * 1998-09-18 2000-03-30 Takeda Chemical Industries, Ltd. Preparations a administrer par voie buccale a liberation lente
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
HU230828B1 (en) 1999-10-29 2018-08-28 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DK1299104T3 (da) 2000-02-08 2009-08-03 Euro Celtique Sa Orale opioidagonistformuleringer sikret mod forfalskning
IL151058A0 (en) 2000-02-08 2003-04-10 Euro Celtique Sa Controlled-release compositions containing opioid agonist and antagonist
WO2002036099A1 (en) * 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
CA2452871C (en) * 2001-07-06 2011-10-04 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
BR0210855A (pt) * 2001-07-06 2006-10-24 Penwest Pharmaceuticals Compan Método de fabricação de formulações de liberação prolongada
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
JP4256259B2 (ja) 2001-07-18 2009-04-22 ユーロ−セルティーク エス．エイ． オキシコドン及びナロキソンの医薬配合物
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
AU2002323032B2 (en) 2001-08-06 2005-02-24 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
CA2708900C (en) 2002-04-05 2019-06-04 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
BR0309620A (pt) * 2002-04-29 2005-03-15 Alza Corp Métodos e formas de dosagem para liberação controlada de oxicodona
US20030224051A1 (en) * 2002-05-31 2003-12-04 Fink Tracy A. Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
CA2491572C (en) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
AU2003270778B2 (en) 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
AU2003272601B2 (en) * 2002-09-20 2009-05-07 Alpharma Pharmaceuticals, Llc Sustained-release opioid formulations and methods of use
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
JP4865330B2 (ja) 2002-12-13 2012-02-01 デュレクト コーポレーション 経口ドラッグデリバリーシステム
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1479381A1 (de) * 2003-05-19 2004-11-24 Euro-Celtique S.A. Pharmazeutische Zusammensetzung enthaltend eine feste Lösung
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
EP2298303A1 (de) 2003-09-25 2011-03-23 Euro-Celtique S.A. Pharmazeutische kombinationen von hydrocodon und naltrexon
CA2541371C (en) * 2003-10-03 2014-12-16 Atul M. Mehta Extended release formulations of opioids and method of use thereof
EP2343073A3 (de) 2003-12-11 2011-10-12 Sepracor Inc. Kombination eines Beruhigungsmittels und eines Neurotransmittermodulators und Verfahren zur Verbesserung der Schlafqualität und Behandlung von Depressionen
DE602005012244D1 (de) * 2004-03-30 2009-02-26 Euro Celtique Sa Manipulationssichere dosierform mit einem adsorbens und einem adversen mittel
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
EP1604667A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung des Restless Leg Syndroms
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
US9308164B2 (en) 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
ES2378671T3 (es) * 2004-09-17 2012-04-16 Durect Corporation Composición anestésica local prolongada que contiene SAIB
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
EP2319499A1 (de) * 2005-01-28 2011-05-11 Euro-Celtique S.A. Alkoholresistente Arzneiformen
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
EP1695700A1 (de) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Darreichungsform enthaltend Oxycodon und Naloxon
EP1855647A4 (de) * 2005-03-04 2010-11-17 Intelgenx Corp Pharmazeutische orale dosierform mit verzögerter freisetzung und herstellungsverfahren dafür
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
ATE464054T1 (de) * 2005-06-09 2010-04-15 Euro Celtique Sa Pharmazeutische zusammensetzung eines neuroaktiven steroids und anwendungen davon
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
EP1813276A1 (de) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Manipulationssichere Dosierformen
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20070281017A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and metal hydroxide
US20070281016A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
MX2008016372A (es) 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
AU2007275034A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
CA2661302A1 (en) * 2006-08-16 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of opioid analgesics
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2117521B1 (de) 2006-11-03 2012-06-27 Durect Corporation Transdermale abgabesysteme mit bupivacain
US20080220064A1 (en) * 2006-12-06 2008-09-11 Ramesh Ketkar Anant Extended release matrix formulations of morphine
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
WO2009088414A2 (en) * 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
PT2405915T (pt) 2009-03-10 2019-01-29 Euro Celtique Sa Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
FR2946533A1 (fr) 2009-06-12 2010-12-17 Ethypharm Sa Reduction des fluctuations plasmatiques d'opioides.
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
SG191288A1 (en) 2010-12-22 2013-07-31 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
ES2581323T3 (es) 2010-12-23 2016-09-05 Purdue Pharma Lp Formas de dosificación oral sólida resistentes a alteraciones
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AR092820A1 (es) 2012-04-17 2015-05-06 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
KR101946103B1 (ko) 2012-07-16 2019-02-08 로드스 테크놀로지즈 개선된 오피오이드 합성을 위한 방법
WO2014013311A1 (en) 2012-07-16 2014-01-23 Rhodes Technologies Process for improved opioid synthesis
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP2983468A4 (de) 2013-03-15 2016-09-07 Durect Corp Zusammensetzungen mit rheologiemodifikator zur reduzierung der auflösungsvariabilität
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2914365C (en) 2013-06-05 2022-03-15 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
MY183489A (en) 2013-07-23 2021-02-22 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
AU2014298257B2 (en) 2013-08-02 2016-11-10 Macfarlan Smith Limited Process for the preparation of oxymorphone
AU2015207734B2 (en) 2014-01-15 2017-02-23 Rhodes Technologies Process for improved oxymorphone synthesis
US9932348B2 (en) 2014-01-15 2018-04-03 Rhodes Technologies Process for improved oxycodone synthesis
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US20180303757A1 (en) 2015-10-23 2018-10-25 Kashiv Pharma Llc Enhanced abuse-deterrent formulations of oxycodone
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3703724A1 (de) 2017-11-02 2020-09-09 NatureCeuticals Sdn. Bhd. Extrakt aus orthosiphon stamineus, formulierungen und verwendungen davon
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
KR20230000634U (ko) 2021-09-16 2023-03-23 장상환 분리가능한 쇠스랑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2805977A (en) 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
ATE14379T1 (de) * 1981-04-27 1985-08-15 Haessle Ab Pharmazeutisches praeparat.
DE3124983A1 (de) * 1981-06-25 1983-01-20 Meditest Inst Fuer Medizinisch Arzneiformen zur oralen verabreichung
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
DK58983D0 (da) * 1983-02-11 1983-02-11 Leo Pharm Prod Ltd Farmaceutisk praeparat
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.

Also Published As

Publication number Publication date
EP0253104B1 (de) 1991-04-10
CN1029770C (zh) 1995-09-20
DK367687D0 (da) 1987-07-15
FI872917A0 (fi) 1987-07-01
PT85353A (en) 1987-08-01
DK367687A (da) 1988-01-19
ES2033259T3 (es) 1993-03-16
FI87045B (fi) 1992-08-14
AU7340387A (en) 1988-01-21
GR3001788T3 (en) 1992-11-23
NO169998B (no) 1992-05-25
CA1296633C (en) 1992-03-03
IN166546B (de) 1990-06-02
NO169998C (no) 1992-09-02
JP2511054B2 (ja) 1996-06-26
MX163284A (es) 1992-04-03
FI87045C (fi) 1992-11-25
IL82604A (en) 1990-08-31
JPS6330427A (ja) 1988-02-09
ZA874038B (en) 1987-12-04
DK175627B1 (da) 2004-12-27
JPH09136845A (ja) 1997-05-27
KR880001285A (ko) 1988-04-22
US4861598A (en) 1989-08-29
EG18574A (en) 1993-08-30
DZ1112A1 (fr) 2004-09-13
EP0253104A1 (de) 1988-01-20
AU596183B2 (en) 1990-04-26
PT85353B (pt) 1990-04-30
IL82604A0 (en) 1987-11-30
CN87104429A (zh) 1988-01-27
FI872917A (fi) 1988-01-19
NZ220406A (en) 1989-08-29
JP2661646B2 (ja) 1997-10-08
ATE62404T1 (de) 1991-04-15
NO872989D0 (no) 1987-07-17
NO872989L (no) 1988-01-19
KR930008954B1 (ko) 1993-09-17

Similar Documents

Publication Publication Date Title
DE3769221D1 (de) Traegermassen fuer die kontrollierte freisetzung pharmazeutischer wirkstoffe.
MX9200875A (es) Compuestos de fluoroalquenilo y su uso como repelentes de pestes.
FR2624732B1 (fr) Formulation pharmaceutique a liberation prolongee
KR890700359A (ko) 안정한 인터페론 복합체
PT85044A (pt) Dispositivo para distribuicao de uma droga difusional
ITRM910080A0 (it) Piede di appoggio di un dispositivo telescopico di appoggio per semirimorchi
FR2634377B1 (fr) Nouvelle forme pharmaceutique a liberation prolongee a base d'un complexe resine-principe actif
FR2389409A1 (de)
MC1991A1 (fr) Esters d'acides carboxyliques pharmacologiquement actifs
LU79186A1 (fr) Procede de preparation d'acides 2-aryl-propioniques optiquement actifs
IT8805224A0 (it) Composizione a base di poliesteri per la liberazione controllata di sostanze medicamentose.
BE863137A (fr) Compositions pharmaceutiques a base d'acides alpha-mercapto-beta-arylacryliques
CH467741A (fr) Procédé de préparation d'acides phénoxy-2 propioniques optiquement actifs
BE877050A (fr) Utilisation d'esters d'acides hydroxycarboxyliques aliphatiques en tant que desodorisants
DE2965364D1 (en) Alpha-difluoromethyl amino acids and pharmaceutical composition containing the same
IT1066095B (it) Composizioni insetticide ed acaricide a base di esteri fenossibenzilici di acidi spirocarbossilici
DE3764084D1 (de) Synthese von tetrahydro-1,1,2,2-perfluoralkanolen und ihren estern.
IT1107955B (it) Composizione acaricida e nematocida a base di esteri di acici ciclopropan-carbossilici
BE866037A (fr) Esterification d'acides carboxyliques aliphatiques
ES2039255T3 (es) Utilizacion de n-((1-etil-2-pirrolidinil)metil)-2-metoxi-5-sulfamoil-benzamida en el tratamiento de la esterilidad.
CS9001478A2 (en) Injection drug form on base of luteolytically active analogue of f2 alpha prostaglandin
FI900626A0 (fi) Menetelmä optisesti aktiivisten 3-tiolanyylisulfonaattiestereiden valmistamiseksi
IT1127194B (it) Dispositivo per variare l'altezza di piano d'appoggio particolarmente adatto all'applicazione su letti per bambini
KR890008326U (ko) 화운데이숀 케이스의 지지상판 착탈장치
FI952684A0 (fi) 19-norsteroideista johdettujen orgaanisten happojen ja alkoholien estereitä

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: THE PURDUE PHARMA CO., STAMFORD, CONN., US

8327 Change in the person/name/address of the patent owner

Owner name: MUNDIPHARMA GMBH, 65549 LIMBURG, DE